Cargando…

Tumorigenicity Studies of Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) for the Treatment of Age-Related Macular Degeneration

Basic studies of human pluripotential stem cells have advanced rapidly and stem cell products are now seeing therapeutic applications. However, questions remain regarding the tumorigenic potential of such cells. Here, we report the tumorigenic potential of induced pluripotent stem cell (iPSC)-derive...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanemura, Hoshimi, Go, Masahiro J., Shikamura, Masayuki, Nishishita, Naoki, Sakai, Noriko, Kamao, Hiroyuki, Mandai, Michiko, Morinaga, Chikako, Takahashi, Masayo, Kawamata, Shin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891869/
https://www.ncbi.nlm.nih.gov/pubmed/24454843
http://dx.doi.org/10.1371/journal.pone.0085336
_version_ 1782299431021838336
author Kanemura, Hoshimi
Go, Masahiro J.
Shikamura, Masayuki
Nishishita, Naoki
Sakai, Noriko
Kamao, Hiroyuki
Mandai, Michiko
Morinaga, Chikako
Takahashi, Masayo
Kawamata, Shin
author_facet Kanemura, Hoshimi
Go, Masahiro J.
Shikamura, Masayuki
Nishishita, Naoki
Sakai, Noriko
Kamao, Hiroyuki
Mandai, Michiko
Morinaga, Chikako
Takahashi, Masayo
Kawamata, Shin
author_sort Kanemura, Hoshimi
collection PubMed
description Basic studies of human pluripotential stem cells have advanced rapidly and stem cell products are now seeing therapeutic applications. However, questions remain regarding the tumorigenic potential of such cells. Here, we report the tumorigenic potential of induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) for the treatment of wet-type, age-related macular degeneration (AMD). First, immunodeficient mouse strains (nude, SCID, NOD-SCID and NOG) were tested for HeLa cells’ tumor-forming capacity by transplanting various cell doses subcutaneously with or without Matrigel. The 50% Tumor Producing Dose (TPD(50) value) is the minimal dose of transplanted cells that generated tumors in 50% of animals. For HeLa cells, the TPD(50) was the lowest when cells were embedded in Matrigel and transplanted into NOG mice (TPD(50) = 10(1.1), n = 75). The TPD(50) for undifferentiated iPSCs transplanted subcutaneously to NOG mice in Matrigel was 10(2.12); (n = 30). Based on these experiments, 1×10(6) iPSC-derived RPE were transplanted subcutaneously with Matrigel, and no tumor was found during 15 months of monitoring (n = 65). Next, to model clinical application, we assessed the tumor-forming potential of HeLa cells and iPSC 201B7 cells following subretinal transplantation of nude rats. The TPD(50) for iPSCs was 10(4.73) (n = 20) and for HeLa cells 10(1.32) (n = 37) respectively. Next, the tumorigenicity of iPSC-derived RPE was tested in the subretinal space of nude rats by transplanting 0.8–1.5×10(4) iPSC-derived RPE in a collagen-lined (1 mm×1 mm) sheet. No tumor was found with iPSC-derived RPE sheets during 6–12 months of monitoring (n = 26). Considering the number of rodents used, the monitoring period, the sensitivity of detecting tumors via subcutaneous and subretinal administration routes and the incidence of tumor formation from the iPSC-derived RPE, we conclude that the tumorigenic potential of the iPSC-derived RPE was negligible.
format Online
Article
Text
id pubmed-3891869
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38918692014-01-21 Tumorigenicity Studies of Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) for the Treatment of Age-Related Macular Degeneration Kanemura, Hoshimi Go, Masahiro J. Shikamura, Masayuki Nishishita, Naoki Sakai, Noriko Kamao, Hiroyuki Mandai, Michiko Morinaga, Chikako Takahashi, Masayo Kawamata, Shin PLoS One Research Article Basic studies of human pluripotential stem cells have advanced rapidly and stem cell products are now seeing therapeutic applications. However, questions remain regarding the tumorigenic potential of such cells. Here, we report the tumorigenic potential of induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) for the treatment of wet-type, age-related macular degeneration (AMD). First, immunodeficient mouse strains (nude, SCID, NOD-SCID and NOG) were tested for HeLa cells’ tumor-forming capacity by transplanting various cell doses subcutaneously with or without Matrigel. The 50% Tumor Producing Dose (TPD(50) value) is the minimal dose of transplanted cells that generated tumors in 50% of animals. For HeLa cells, the TPD(50) was the lowest when cells were embedded in Matrigel and transplanted into NOG mice (TPD(50) = 10(1.1), n = 75). The TPD(50) for undifferentiated iPSCs transplanted subcutaneously to NOG mice in Matrigel was 10(2.12); (n = 30). Based on these experiments, 1×10(6) iPSC-derived RPE were transplanted subcutaneously with Matrigel, and no tumor was found during 15 months of monitoring (n = 65). Next, to model clinical application, we assessed the tumor-forming potential of HeLa cells and iPSC 201B7 cells following subretinal transplantation of nude rats. The TPD(50) for iPSCs was 10(4.73) (n = 20) and for HeLa cells 10(1.32) (n = 37) respectively. Next, the tumorigenicity of iPSC-derived RPE was tested in the subretinal space of nude rats by transplanting 0.8–1.5×10(4) iPSC-derived RPE in a collagen-lined (1 mm×1 mm) sheet. No tumor was found with iPSC-derived RPE sheets during 6–12 months of monitoring (n = 26). Considering the number of rodents used, the monitoring period, the sensitivity of detecting tumors via subcutaneous and subretinal administration routes and the incidence of tumor formation from the iPSC-derived RPE, we conclude that the tumorigenic potential of the iPSC-derived RPE was negligible. Public Library of Science 2014-01-14 /pmc/articles/PMC3891869/ /pubmed/24454843 http://dx.doi.org/10.1371/journal.pone.0085336 Text en © 2014 Kanemura et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Kanemura, Hoshimi
Go, Masahiro J.
Shikamura, Masayuki
Nishishita, Naoki
Sakai, Noriko
Kamao, Hiroyuki
Mandai, Michiko
Morinaga, Chikako
Takahashi, Masayo
Kawamata, Shin
Tumorigenicity Studies of Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) for the Treatment of Age-Related Macular Degeneration
title Tumorigenicity Studies of Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) for the Treatment of Age-Related Macular Degeneration
title_full Tumorigenicity Studies of Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) for the Treatment of Age-Related Macular Degeneration
title_fullStr Tumorigenicity Studies of Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) for the Treatment of Age-Related Macular Degeneration
title_full_unstemmed Tumorigenicity Studies of Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) for the Treatment of Age-Related Macular Degeneration
title_short Tumorigenicity Studies of Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) for the Treatment of Age-Related Macular Degeneration
title_sort tumorigenicity studies of induced pluripotent stem cell (ipsc)-derived retinal pigment epithelium (rpe) for the treatment of age-related macular degeneration
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891869/
https://www.ncbi.nlm.nih.gov/pubmed/24454843
http://dx.doi.org/10.1371/journal.pone.0085336
work_keys_str_mv AT kanemurahoshimi tumorigenicitystudiesofinducedpluripotentstemcellipscderivedretinalpigmentepitheliumrpeforthetreatmentofagerelatedmaculardegeneration
AT gomasahiroj tumorigenicitystudiesofinducedpluripotentstemcellipscderivedretinalpigmentepitheliumrpeforthetreatmentofagerelatedmaculardegeneration
AT shikamuramasayuki tumorigenicitystudiesofinducedpluripotentstemcellipscderivedretinalpigmentepitheliumrpeforthetreatmentofagerelatedmaculardegeneration
AT nishishitanaoki tumorigenicitystudiesofinducedpluripotentstemcellipscderivedretinalpigmentepitheliumrpeforthetreatmentofagerelatedmaculardegeneration
AT sakainoriko tumorigenicitystudiesofinducedpluripotentstemcellipscderivedretinalpigmentepitheliumrpeforthetreatmentofagerelatedmaculardegeneration
AT kamaohiroyuki tumorigenicitystudiesofinducedpluripotentstemcellipscderivedretinalpigmentepitheliumrpeforthetreatmentofagerelatedmaculardegeneration
AT mandaimichiko tumorigenicitystudiesofinducedpluripotentstemcellipscderivedretinalpigmentepitheliumrpeforthetreatmentofagerelatedmaculardegeneration
AT morinagachikako tumorigenicitystudiesofinducedpluripotentstemcellipscderivedretinalpigmentepitheliumrpeforthetreatmentofagerelatedmaculardegeneration
AT takahashimasayo tumorigenicitystudiesofinducedpluripotentstemcellipscderivedretinalpigmentepitheliumrpeforthetreatmentofagerelatedmaculardegeneration
AT kawamatashin tumorigenicitystudiesofinducedpluripotentstemcellipscderivedretinalpigmentepitheliumrpeforthetreatmentofagerelatedmaculardegeneration